Gilead Sciences, Inc. Market Performance Review - February 12, 2026
Stock Performance Overview
On February 12, 2026, Gilead Sciences, Inc. (ticker: GILD) experienced a notable decline in its stock price, closing at $151.81, down $3.99 or 2.56% from the previous close of $155.80. The stock opened at $153.42, reached a high of $155.73, and a low of $150.82 during the trading session. The trading volume was approximately 9.89 million shares, with a total market capitalization of about $188.4 billion.
Key Financial Results
Gilead's recent financial results, announced on February 10, 2026, revealed a mixed performance. For the fourth quarter of 2025, Gilead reported total revenues of $7.9 billion, a 5% increase compared to the same quarter in 2024. The diluted earnings per share (EPS) for Q4 2025 was $1.74, up from $1.42 in Q4 2024. However, the non-GAAP diluted EPS decreased slightly to $1.86 from $1.90 year-over-year.
For the full year 2025, Gilead's total revenues reached $29.4 billion, a 2% increase from the previous year. The full-year diluted EPS was $6.78, a significant rise from $0.38 in 2024. The company’s cash reserves stood at $10.6 billion as of December 31, 2025, reflecting a solid liquidity position.
Dividend Announcement
In conjunction with the financial results, Gilead announced a 3.8% increase in its quarterly dividend, raising it to $0.82 per share. This dividend is set to be paid on March 30, 2026, to shareholders on record as of March 13, 2026. The announcement of the dividend increase is generally viewed positively by investors, as it indicates the company's commitment to returning value to shareholders.
Analyst Reactions
Analysts had mixed reactions to Gilead's financial results. While the quarterly results exceeded Wall Street estimates, the guidance for 2026 fell at the lower end of expectations. Gilead projected product sales between $29.6 billion and $30.0 billion for 2026, with diluted EPS expected to range from $6.75 to $7.15. This conservative outlook led to some disappointment among analysts, contributing to the stock's decline on the following trading days.
TD Cowen raised its price target for Gilead from $145.00 to $160.00, maintaining a "buy" rating, which reflects a positive long-term outlook despite the short-term volatility.
Market Sentiment and External Factors
The broader market sentiment on February 12, 2026, was influenced by various macroeconomic factors, including investor concerns over inflation and interest rates. The overall market was experiencing fluctuations, with many stocks reacting to economic indicators and geopolitical developments. Gilead's performance was not isolated; it was part of a larger trend affecting healthcare stocks amid mixed economic signals.
Conclusion
In summary, Gilead Sciences, Inc. faced a challenging trading day on February 12, 2026, with its stock price declining in response to mixed financial results and cautious guidance for the upcoming year. The company’s solid revenue growth and dividend increase were overshadowed by concerns regarding future performance and market conditions. Analysts' mixed reactions and external economic factors contributed to the stock's downward movement, making it essential for investors to closely monitor Gilead's developments in the coming months.
Explore more exclusive insights at nextfin.ai.
